GT Medical Technologies is redefining the treatment of operable brain tumors. Founded by brain tumor specialists and medical device innovators, GT Medical was created to address critical gaps in how these tumors are treated - and to challenge the limitations of conventional therapies.
We develop innovative, surgically integrated therapies designed to deliver treatment with greater precision, improve clinical outcomes, and elevate the standard of care for patients.
To learn more about our ongoing clinical trials, click here.
GammaTile®, our first FDA-cleared technology, exemplifies our mission.
Designed for patients with operable brain tumors, GammaTile is a surgically implantable, bioabsorbable tile-based radiation therapy placed directly into the tumor cavity at the time of tumor resection.
By delivering radiation from within the surgical cavity, GammaTile provides precise, localized tumor control while limiting exposure to surrounding healthy brain tissue. This intraoperative approach is proven to help reduce tumor recurrence and improve patient outcomes.1
Since its full U.S. market launch in March 2020, GammaTile has been adopted by numerous leading cancer centers across academic and community settings, reflecting growing confidence in GT Medical’s approach and the clinical impact of its technology.
OUR LEADERSHIP
Per Langoe
Chief Executive Officer
Michael Garcia, MD, MS
Chief Medical Officer and Head of Clinical Development
James Leech
Chief Financial and Strategy Officer
Ole Mikkelsen, MBA
Chief Operating Officer
Richard Low
Chief Marketing Officer
Jeff Lewis
Chief Commercial Officer
Anthony Smith
Senior Vice President of Operations
OUR FOUNDERS
David G. Brachman, MD, FASTRO
Co-Founder and Chief Technology Officer
Heyoung McBride, MD, MS, FASTRO
Co-Founder
Peter Nakaji, MD
Co-Founder
The late Emad Youssef, MD
Co-Founder
Theresa Thomas, MS, CCRC
Co-Founder